nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins
|
Zeng, Junquan |
|
|
93 |
4 |
p. 381-391 |
artikel |
2 |
CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms
|
Wang, Yuanpei |
|
|
93 |
4 |
p. 295-306 |
artikel |
3 |
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study
|
Biesdorf, Carla |
|
|
93 |
4 |
p. 329-339 |
artikel |
4 |
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer
|
Lambert, Marie |
|
|
93 |
4 |
p. 393-395 |
artikel |
5 |
Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study
|
Takahashi, Hiroaki |
|
|
93 |
4 |
p. 319-328 |
artikel |
6 |
Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients
|
Westerdijk, K. |
|
|
93 |
4 |
p. 353-364 |
artikel |
7 |
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults
|
Chen, Yizhe |
|
|
93 |
4 |
p. 307-317 |
artikel |
8 |
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
|
Matsubara, Nobuaki |
|
|
93 |
4 |
p. 341-352 |
artikel |
9 |
Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule
|
Kobuchi, Shinji |
|
|
93 |
4 |
p. 365-379 |
artikel |
10 |
Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy
|
Ji, Yan |
|
|
93 |
4 |
p. 273-293 |
artikel |